Our team of epidemiologists, biostatisticians, data scientists, and clinicians is here to help you achieve your business objectives from launch to commercialization. Notably, we can help optimize clinical trials and run epidemiological assessments. One data source may not fully answer a question, and therefore we use a combination of prospective and retrospective data sources. Learn about our data collection endeavors here.
HDI Group provides the expertise you need in all clinical trial development stages using epidemiology and industry insights. HDI Group Company augments your company’s intelligence in running clinical trials by unveiling successful initiatives worldwide, predicting enrollment, or building local capacity. Our capabilities include:
Design, plan and conduct clinical trials
Establish the incidence and prevalence rate
Collect and interpret the clinical trial data
Post hoc analyses of clinical trials data to address emergent safety issues and secondary endpoints
Carry out meta-analysis and network meta-analysis of pooled clinical trial data
Predict and monitor trial enrollment, cost, and quality
Evaluate the drug development pipeline by phase globally
Identify top therapeutic focus areas, targets, and mechanisms
Conduct ad hoc analyses of clinical trial data to address emergent drug safety issues and to analyze secondary endpoints, such as quality-of-life measures, in the trials
Select sites, patients, and the required hospitals
Develop economic analysis alongside clinical trials
Run efficacy and safety analysis of phase I-IV clinical trials
Indirect product comparisons across clinical trials when head-to-head trials are not available
Run personalized or precision medicine analysis to identify high-value subgroups
Optimize patient and compliance monitoring
Evaluate the findings and methodological rigor of current trials running globally
Analyze clinical trial data concerning efficacy and safety to address questions regarding the drug’s patent and the potential to make and sell a generic form before the patent’s expiration
Pharmaceutical companies need an accurate, detailed picture of patient experience and outcomes in clinical trials and the real world to develop and deliver effective drugs. When RCTs are not feasible, several quasi-experimental and non-experimental studies could better monitor pathology evolution and therapeutic strategies. Our capabilities include:
Identify promising gene and biomarker combinations for clinical trial stratification and analysis\ Understand the disease
Characterize patient populations and identify subgroups of interest
Understand the natural history of the disease/treatment pathway
Determine the standard of care
Identify unmet needs
Identify suitable local comparators
Run patient flow analysis/patient journey
Run adherence studies
Evaluate off-label use
Identify molecular correlates of drug response based on internal and external screening data
Run descriptive prevalence and incidence studies
Run pharmacovigilance and spontaneous report adverse event analyses
Run post-marketing drug safety epidemiology studies
Use registries and run active surveillance
Perform quality of life and patient-reported outcome studies
Run risk-benefit analysis
Demonstrate cost-effectiveness of drug therapy
Develop procedures and instruments for patient-reported outcomes
Develop analytical decision models
Develop Budget impact analysis/ forecast
Develop Health economic analysis of sponsors’ product portfolio
Detect potential for health economic value propositions
Detect need for health economic value defense lines
Analyze sponsors’ health economics strategies and planning
Run evidence appraisal and synthesis
HDI Group integrates unparalleled data, transformative technology, advanced analytics, and domain expertise and puts it seamlessly within reach.
Multiple data types from the world’s most reliable sources, constantly gathered, updated, and usably integrated.
Domain experts worldwide can support you, from sales analytics and forecasting to competitive intelligence, data cleaning, and coding.
Machine learning that projects future-facing, data-based insights.
Our close collaborators have studied globally at the top 10 universities (Cambridge, MIT, Johns Hopkins University, Harvard Univ., Clark Univ., LSE).
To know more about our projects and training contact us.